Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Raymond Smith, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Matthew Smith and Philip Saylor.
Connection Strength

5.556
  1. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4.
    View in: PubMed
    Score: 0.524
  2. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012 Jul 01; 18(13):3677-85.
    View in: PubMed
    Score: 0.502
  3. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011 Sep 20; 29(27):3705-14.
    View in: PubMed
    Score: 0.477
  4. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2011 Aug; 186(2):482-6.
    View in: PubMed
    Score: 0.471
  5. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61.
    View in: PubMed
    Score: 0.460
  6. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5.
    View in: PubMed
    Score: 0.438
  7. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):211-23.
    View in: PubMed
    Score: 0.428
  8. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94.
    View in: PubMed
    Score: 0.421
  9. Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol. 2009 Oct; 6(10):529-31.
    View in: PubMed
    Score: 0.419
  10. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8.
    View in: PubMed
    Score: 0.403
  11. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50.
    View in: PubMed
    Score: 0.142
  12. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94.
    View in: PubMed
    Score: 0.133
  13. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. Eur Urol. 2014 Mar; 65(3):642-9.
    View in: PubMed
    Score: 0.132
  14. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013 Feb; 63(2):309-20.
    View in: PubMed
    Score: 0.130
  15. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012 Nov; 53(11):1670-5.
    View in: PubMed
    Score: 0.128
  16. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.
    View in: PubMed
    Score: 0.123
  17. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010 Dec 01; 8(1):29-36.
    View in: PubMed
    Score: 0.113
  18. Treatment and prevention of bone complications from prostate cancer. Bone. 2011 Jan; 48(1):88-95.
    View in: PubMed
    Score: 0.110
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.